lilly glp-1 FDA asks for more safety data on weight loss pill Foundayo Eli Lilly & Co. presents
Description
Nguyen T, Gong M, Wen S, Yuan X, Wang C, Jin J, et al
So, what does this suggest for the future of obesity treatment
References 1.Meier JJ
Tailored dosage adjustments based on your individual response
GI side effects broadly in line with injectables
In summary, tirzepatide modulates metabolic and inflammatory pathways that may enhance airway stability in obesity-related OSAS (Figure 2)
